Lima Corporate is hailing the recent release its new total knee replacement innovation, the Physica System. This system is based on technology research that combines the concept of natural knee movement with an advanced biomechanical design.
Lima Corporate Releases Physica Knee System
1 min read Premium comments
Secondary
The Physica System includes three types of total knee implants: Physica KR (Kinematic Retaining), Physica PS, and a Cruciate Retaining version. The Physica PS and CR are available in Europe. Orthopedic surgeons have a wide variety of sizes and options available, which will help them achieve a more physiological outcome. The company has also developed instrumentation for the Physica System.
Luigi Ferrari, CEO of Lima Corporate, told OTW, “This Physica System is based on novel technology that combines the concept of natural knee movement with an advanced biomechanical design. In particular, the Physica KR implant induces natural knee kinematics, through its unique patented design of the articulating surfaces. The Physica PS implant is characterized by an asymmetric cam which allows an optimized knee kinematic profile and load transmission through the tibial post.”
“The Physica System is currently sold throughout Europe and we are introducing the system into new centers at a rapid rate and we have a number of clinical trials on-going. In the U.S., where we have already obtained FDA approval for the Physica KR, we will approach this large market through targeted centers throughout the next year.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.